Background: Outcomes of HIV-infected children before widespread use of antiretroviral therapy (ART) for treatment and prevention of motherto-child transmission (PMTCT) have been well characterized but less is known about children who acquire HIV infection in the context of good ART access. Methods: We enrolled newly diagnosed HIV-infected children ≤24 months of age at 3 hospitals and 2 clinics in Johannesburg, South Africa. We report ART initiation and mortality rates during 6 months from enrollment and factors associated with mortality. Results: Of 272 children enrolled, median age 6.1 months, 69.5% were diagnosed during hospitalization. By 6 months postenrollment, 53 (19.5%) died and 73 (26.8%) were lost-to-follow-up. Using Kaplan-Meier analysis, the probability of death by 6 months after enrollment was 23.5%. Conclusions: ART initiation is highly protective against death in young children. However, despite improved access to ART, young children remain at risk for early death; innovative approaches to rapidly diagnose and initiate treatment as early in life as possible are needed.
S
outh Africa has documented remarkable success in preventing and treating pediatric HIV infection. In 2014, mother-to-child HIV transmission (MTCT) rates were estimated at 4.0% 1,2 and more than 150,000 children initiated antiretroviral treatment (ART). 2, 3 While decreased mortality among HIV-infected adults and children was demonstrated, [4] [5] [6] [7] [8] there were an estimated 12,000 deaths among children less than 14 years of age in 2014. 2 Over the last decade, new scientific findings have been incorporated into South African guidelines. In 2008, the Option A prevention of MTCT (PMTCT) approach was introduced, modified in 2010, followed by adoption of Option B in 2013 and Option B+ in 2015. [9] [10] [11] In parallel, early infant diagnostic (EID) testing using dried blood spots for polymerase chain reaction testing was scaled-up. 12, 13 Pediatric treatment recommendations have also evolved rapidly. In response to the children with HIV early antiretroviral therapy (CHER) study, treatment was recommended for all children less than 12 months of age, subsequently extended to include all children less than age 5.
14 In South Africa, protease inhibitor-based therapy was always recommended for infants regardless of prior nevirapine exposure for PMTCT. 15, 16 Similar advances have been documented in many highburden countries in Sub-Saharan Africa, but hundreds of thousands of children continue to acquire perinatal HIV infection. 2, 17, 18 While health outcomes before widespread availability of ART have been described, 19 we know less about children who acquire HIV in the context of good access to EID and to antiretrovirals for prevention and treatment.
In 2011, we conducted a surveillance study of all infants and young children diagnosed with HIV infection at the 3 hospitals and 2 clinics in Johannesburg/Soweto, South Africa, to support their engagement in care and ART initiation. We describe mortality in these children over the first 6 months after study enrollment.
METHODS

Study Population
We conducted a surveillance study aimed to recruit all newly diagnosed HIV-infected children ≤2 years of age at Rahima Moosa Mother and Child Hospital, Charlotte Maxeke Johannesburg Academic Hospital, Chris Hani Baragwanath Academic Hospital, Perinatal HIV Research Unit clinic and Witkoppen clinic in Johannesburg, South Africa, January-December 2011. Children were identified at inpatient and outpatient services by facility health workers and study staff according to eligibility criteria: child ≤24 months with a positive HIV polymerase chain reaction if ≤18 months or a positive HIV antibody test if >18 months; mother/ primary caregiver had not yet received test results or received results within the past 2 weeks. Children already on ART were enrolled if the other criteria were met. The study was approved by the Institutional Review Boards of the University of the Witwatersrand and Columbia University.
Study Procedures
At enrollment, mothers completed a questionnaire detailing: socioeconomic status, HIV care and PMTCT, infant feeding, barriers to care, disclosure, alcohol consumption, stigma and psychologic distress. Whenever possible, clinical parameters reported in the questionnaire were verified in medical records. Blood samples were collected from mother and child for plasma HIV RNA viral load (VL) (Roche Taqman HIV-1 Test v2.0, Roche Molecular Systems, Inc., Branchburg, NJ) and CD4 cell count/percent. Study staff assisted families to ensure that all participants enrolled in care and initiated ART expeditiously. HIV care and ART was provided, free of charge, at the study facilities according to national guidelines, which specified ART initiation for all children less than 2 years of age.
11 After 6 months, clinical status and laboratory results were abstracted from medical records. For those whose status could not be determined on record review, attempts were made to reach the family telephonically.
Statistical Analysis
Enrollment characteristics were summarized using, for categorical variables, simple proportions and, for continuous variables, means, medians and interquartile range (IQR). Sex-and ageadjusted weight-for-age (WAZ) and height-for-age Z scores were calculated using World Health Organization norms. 20 We used twosample t test or Wilcoxon signed rank test to compare normally and nonnormally distributed continuous variables, respectively. Categorical data were compared using the χ 2 test. The primary outcome was child mortality within 6 months of enrollment. We used the Kaplan-Meier method to calculate the cumulative probability of death by 6 months after enrollment overall and stratified by key covariates. Cox proportional hazard models were used to analyze which enrollment characteristics were potential risk factors for mortality. Characteristics were classified into fixed covariate categories except ART initiation, which was considered as a time-dependent variable. To take loss-to-follow-up adequately into account in this model, we imputed ART-free survival time to 6 months postenrollment for those lost-to-follow-ups before 6 months. Unadjusted hazard ratios (HRs) and respective 95% confidence intervals (CIs) were reported. The role of confounding and mediation was investigated in stratified analysis and systematic multivariable Cox proportional models. Final models accounted for biologically meaningful relationships, potential confounders that changed main effects by more than 10%, and statistical significance (P < 0.05) of retained covariates. Proportional hazard assumptions were tested by checking martingale residuals for each important covariate. Statistical analyses were performed using SAS 9.3 (SAS Institute Inc., Cary, NC).
RESULTS
Cohort Description
Overall 289 children were enrolled; 272 were included in analysis, excluding 17 children (5.9%) already on ART. Of 272 ART-naive children, 52.2% female, the median age at enrollment was 6.2 months ( Table 1 ). The majority (69.5%) were identified as HIV infected during the hospital admission, 20.7% in PMTCT follow-up and 9.8% through immunization services. The median age at HIV diagnostic testing was 3.7 months (IQR: 1.6-9.1). Children identified during hospital admission were older at testing (median: 6.0 months, IQR: 2.6-12.9) than those tested in PMTCT follow-up (median: 1.6 months, IQR: 1.5-3.3). A third (33.1%) had no PMTCT antiretroviral exposure (maternal or infant), 51.5% had been exposed to antiretroviral prophylaxis (maternal, infant or both but excluding maternal ART) and 15.4% had mothers who received ART during pregnancy. Approximately half had ever breastfed (53.2%) and 15.4% were breastfeeding at enrollment.
For 261 children with CD4 testing at enrollment, the median CD4 was 20.0% (IQR: 12.5%-28.9%) ( Table 1) . HIV RNA VL was available for 244 children. Median VL was 1,226,150 copies/mL (IQR: 393,905-4,890,899 copies/mL) and was lower among children older than 12 months of age (752,867 copies/mL) compared with those less than 6 months of age (1,610,059 copies/mL) and 6-12 months of age (1,261,398 copies/mL) at enrollment.
Mortality
By 6 months after enrollment, 53 children (19.5%) had died and 73 children (26.8%) were no longer in care at the study facility (Fig. 1) . Among those not retained, 18 (24.7%) were known to have relocated outside of Johannesburg, 20 (27.3%) were reported alive, and the status of the other 35 (47.9%) was unknown. Only 146 (53.7%) children were alive and known to be retained in care 6 months after enrollment. Using Kaplan-Meier analysis, the probability of death by the first week after enrollment was 4.7% (n = 12), by 1 month 9.6% (n = 24), by 3 months 18.1% (n = 43) and by 6 months 23.5% (n = 53). The median age of death was 9.1 months (95% CI: 8.6-12.0).
ART Initiation
Among 226 (83.1%) children who initiated ART within 6 months of study enrollment (Fig. 1) , the median time to initiation was 8 days after study enrollment (95% CI: 6.0-12.0); 23 days after HIV diagnostic test results were provided (95% CI: 18.0-27.0) and 36 days from time of blood draw for the most recent diagnostic test (95% CI: 31.0-40.0). All 146 children who were alive and in follow-up at 6 months initiated ART, whereas only 52.8% (28/53) of those who died and 71.2% (52/73) of those who were lost to follow-up before 6 months were known to have initiated ART. Among the group of children who ever started treatment, there was little difference in the median time of ART initiation among those children who died (10 days, 95% CI: 5.0-18.0) versus those who survived (8 days, 95% CI: 6.0-12.0, P = 0.3007).
Risk Factors for Mortality
ART initiation, treated as a time-dependent variable, was associated with a 71% reduction in the risk of death [HR = 0.29 (95% CI: 0.15-0.58)] ( Table 2 ). Identification as HIV infected during a hospital admission was associated with an almost 4-fold risk of death [HR = 3.92 (95% CI: 1.66-9.22] compared with identification during PMTCT follow-up or immunization services. Children with more advanced HIV disease were at increased risk for mortality, including those with CD4 ≤20%, VL ≥1,500,000 copies/mL and WAZ ≤ −2 standard deviation (SD). Age at enrollment was not associated with mortality risk.
In multivariable analysis adjusting for all the variables shown in Table 2 Several maternal health and social characteristics were also associated with child mortality in univariable analysis (Table 2) . Receiving no PMTCT antiretrovirals (mother or infant) was associated with a doubling in mortality risk [HR = 2.05 (95% CI: 1.12-3.76)] compared with receipt of any PMTCT. Maternal advanced disease (CD4 count ≤350/no ART) also significantly increased child mortality compared with women with higher CD4 counts/no ART [HR = 2.89 (95% CI: 1.36-6.14)] ( Table 2 , Figs. 2A, B) . Children born to immigrant mothers had an increased risk of death [HR = 1.84 (95% CI: 1.05-3.23)] compared with children of South African mothers. Less maternal education was associated with an increased risk of child death. Children of women reporting positive experiences with antenatal staff were at lower risk for mortality but very few women reported other than positive experiences.
In multivariable analysis including treatment initiation and all of the variables in Table 2 except experience with the nurses and counselors (which were not retained because of the small numbers), (Table 3) .
DISCUSSION
Despite broad access to early infant diagnosis and HIV prevention and treatment services in South Africa, HIV-infected infants and young children remain at high risk for poor health outcomes including early mortality. Among 272 children less than 2 years of age diagnosed with HIV in Johannesburg/Soweto in 2011, one third had not received any maternal or infant antiretrovirals for PMTCT and the majority was diagnosed on hospital wards, with evidence of advanced HIV disease. Most children (83%) successfully initiated ART, but even with extra support engagement provided in our project, it generally took 4-6 weeks from diagnostic testing to start ART. While ART initiation markedly decreased the risk of death, 19.5% of children died and 26.8% were lost over 6 months of follow-up. These findings underscore the extreme vulnerability of perinatally infected infants and the urgent need to better engage and retain women and their children in PMTCT and treatment services.
We aimed to identify all HIV-infected children ≤2 years of age at 5 health facilities in Johannesburg/Soweto in 2011 and facilitate enrollment and rapid ART initiation. Among the 226 children who started treatment, the median time to initiation was 8 days after enrollment and 36 days from diagnostic testing. Delays along the EID cascade have been well delineated and in comparison to many settings, 7-8 weeks from testing to treatment appears relatively efficient. 21 However, early in life, even the shortest delays can jeopardize the health of these vulnerable children. The introduction of EID point of care technology has the potential to accelerate diagnosis, facilitate earlier treatment initiation and further reduce mortality. 22 We found, not surprisingly, that ART was highly effective, reducing the risk of death 4-fold. Unfortunately, despite the availability of staff to help families access services, not all children started treatment. Initiation rates were notably low among those who died (71.2%) and were lost-to-follow-up (52.8%). A quarter of the children lost to study transferred care and equally as many were reported alive when families were contacted but we believe that some proportion of children for whom we have no information likely died. Braitstein et al 23 selected a random sample of HIV-infected children lost-to-follow-up in Kenya for home tracing. Health workers located 36 (82%) of 44 children: 7 (16%) were reported dead.
Innes et al 24 described disease status among 403 South African infants identified 2007-2010. Treatment was initiated at a median age of 8.4 months, and 62% had advanced disease at treatment start. In this cohort, many had advanced disease at diagnosis 24 and indicators of disease progression were associated with mortality: diagnosis during hospitalization, low CD4 and poor growth. Neither child age nor VL was predictive of mortality when other factors were considered. Some children with advanced disease likely died before treatment initiation or were too compromised to respond. In Francistown, Botswana, 79 of 202 HIV-infected infants died, 56 before ART initiation and 23 on ART with most deaths attributed to pneumonia, sepsis and gastroenteritis. 25 Wagner et al, 26 reporting outcomes of 99 early diagnosed infants in Kenya, 2005 Kenya, -2007 , found that children diagnosed during hospital admissions were 3 times more likely to die We also delineate a relationship between maternal health and health seeking behaviors with child health outcomes. We found that children born to women with low CD4 (≤350 cells/mm 3 ) who were not on treatment were at substantially higher risk for mortality compared with healthier women. The association between maternal and child health outcomes has been described in perinatal HIV: poor maternal health confers increased risk of MTCT, infant disease progression and death. [30] [31] [32] [33] These women were eligible for ART but either did not engage in care or were not initiated on ART. In an analysis of PMTCT uptake among mothers in this cohort, we found that among women enrolled in PMTCT care, only 1 in 3 meeting eligibility criteria was prescribed ART. 34 Barriers to ART initiation under Option A, the PMTCT approach at the time of this study, have been well described. [35] [36] [37] We also found that children with any PMTCT exposure (maternal and/or infant antiretrovirals) had better outcomes than those with no PMTCT. This included reduced mortality as well as lower VLs and higher CD4% at enrollment. We hypothesize that in utero and postnatal antiretrovirals may attenuate disease progression among infected infants. Antiretroviral drugs even when given in PMTCT regimens may act to lower maternal and infant VL, thereby limiting establishment of the infant viral reservoir, lowering viral set point and slowing disease progression. However, it is possible that nonbiologic explanations may also play a role.
Our findings provide further support for the addition of diagnostic testing at delivery into the testing algorithm for EID. The majority of children in our study were identified outside of PMTCT programs. We have previously shown that failure to diagnose HIV infection during pregnancy was a primary reason for missing both PMTCT and EID. 34 Furthermore, MTCT among women who acquire HIV during pregnancy also contributes disproportionately to new pediatric infections. 18 In South Africa where the rate of institutional delivery is high, antibody testing of women with negative and/or unknown status coupled with diagnostic testing at birth of all HIV-exposed babies offers a safety net to new mothers, ensuring that they learn their diagnosis of HIV infection, and expedites the diagnosis of infected children. South Africa recently endorsed birth testing as national policy. 38 There are several limitations to our study. As we only enrolled children at 5 facilities in Johannesburg, our findings may not be generalizable to children treated in other settings or to children born after the introduction of Option B+. However, we note that many HIV high-burden countries in Sub-Saharan Africa, while endorsing the Option B+ approach, have yet to scale up both universal ART for pregnant women and well-functioning EID services for exposed infants.
Another limitation is that clinical outcomes could not be determined for 25% of children. This lost-to-follow-up rate is consistent with what is commonly reported in HIV service programs. 23, 29 Finally, while we have one of the largest pediatric cohorts of young children diagnosed in a single calendar year, the sample size limited our ability to fully define the specific contributions of each maternal and infant factor.
Despite advances in prevention and treatment, infants with HIV infection remain at high risk for early death. Incomplete uptake and retention across the PMTCT cascade results in delayed diagnosis often only when the child is seriously ill. The implementation of Option B+ should improve maternal ART uptake but other measures such as diagnostic testing at birth will ensure timely diagnosis and successful treatment of those children who acquire HIV infection.
